Mainstay Medical announces the completion of all implants in the ReActiv8-B Study
Dublin, Ireland: 9 July 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces the completion of all implants in ReActiv8-B, its US IDE clinical study.
A total of 204 patients were implanted in the study, reflecting the strength of interest in study participation. The implants were completed in accordance with the Company's planned timeline and the Company expects to announce a full data readout towards the end of 2018.
More info on Mainstay Medical's website.
Next > Sequana Medical announces the appointment of Kirsten Van Bockstaele as Chief Financial Officer
Previous > Green Biologics announces launch of first bio-based acetone nail polish remover to be introduced in Sally Beauty stores nationwide